aluxum/E+ via Getty Images
Relmada Therapeutics (NASDAQ:RLMD) added ~13% on Tuesday as Jefferies upgraded the biotech, citing a potential turnaround story due to an upcoming Phase 3 readout for its lead asset, REL-1017 targeted at depression.
The experimental therapy for major depressive disorder (MDD) is expected to generate interim
